Temozolomide

Mycosis Fungoides, Advance Directives, Radiotherapy + 11 more
Treatment
20 Active Studies for Temozolomide

What is Temozolomide

TemozolomideThe Generic name of this drug
Treatment SummaryTemozolomide is a medication used to treat brain tumors such as refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV). It is a prodrug that is taken orally or through injection, and it works by releasing a highly reactive methyl diazonium cation that leads to DNA damage and eventual cell death. Temozolomide is the standard of care for these types of tumors and was approved by the FDA in 1999 and 2009. It is marketed under the name TEMODAR® by Merck.
Temodaris the brand name
image of different drug pills on a surface
Temozolomide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Temodar
Temozolomide
1999
164

Effectiveness

How Temozolomide Affects PatientsTemozolomide is a drug that works by attacking and damaging DNA in cells, leading to their death. This drug can cause myelosuppression (lowered production of white and red blood cells), myelodysplastic syndrome, secondary malignancies, and myeloid leukemia. Pneumonia and liver damage are also possible side effects and patients must be monitored for these issues throughout their course of treatment. Animal studies have found that this drug can have serious effects on unborn babies, so male and female patients should use contraception for three and six months after their last dose.
How Temozolomide works in the bodyGlioblastoma is a type of brain tumor treated with radiotherapy and chemotherapy, usually with a drug called temozolomide. Temozolomide is a small molecule that breaks down in the body to form an agent that can attach to the DNA in cancer cells. This agent specifically targets guanine in the DNA, which causes the cell to die or prevents it from reproducing. It can also alter the number of immune system cells in the tumor, which may enhance the effectiveness of immunotherapies.

When to interrupt dosage

The proposed dose of Temozolomide is contingent upon the diagnosed ailment, such as Refractory Ewing Sarcoma, melanoma and Glioblastoma. The quantity of dosage fluctuates, as per the method of administration (e.g. Capsule or Intravenous) featured in the table beneath.
Condition
Dosage
Administration
Disease Progression
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advance Directives
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Glioblastoma
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Nitrosourea treatment
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Procarbazine treatment
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Sarcoma, Ewing
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Anaplastic astrocytoma
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Radiotherapy
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Mycosis Fungoides
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advance Directives
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
melanoma
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Primary Central Nervous System Lymphoma (PCNSL)
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Soft Tissue Sarcoma
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Neuroblastoma
5.0 mg, , 20.0 mg, 100.0 mg, 250.0 mg, 140.0 mg, 180.0 mg, 2.5 mg/mL, 10.0 mg/mL
, Oral, Capsule, Capsule - Oral, Powder, for solution - Intravenous, Powder, for solution, Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Warnings

Temozolomide has one contraindication, and thus should be avoided in cases where the conditions in the following table are present.Temozolomide Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Temozolomide may interact with Pulse Frequency
There are 20 known major drug interactions with Temozolomide.
Common Temozolomide Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Temozolomide is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Temozolomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Temozolomide is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Temozolomide is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Temozolomide is combined with Acteoside.
Temozolomide Toxicity & Overdose RiskTaking high doses of temozolomide can lead to myelosuppression, which is reduced production of blood cells. This can cause infection and death. For example, one patient who took 2000 mg/day for five days suffered from decreased production of all types of blood cells, fever, and failure of multiple organs, which eventually led to death. If someone overdoses on temozolomide, they should be monitored for changes in their blood count and given supportive care if needed.
image of a doctor in a lab doing drug, clinical research

Temozolomide Novel Uses: Which Conditions Have a Clinical Trial Featuring Temozolomide?

217 active trials are being conducted to assess the potential of Temozolomide to treat melanoma, Primary Central Nervous System Lymphoma (PCNSL) and Glioblastoma.
Condition
Clinical Trials
Trial Phases
Anaplastic astrocytoma
0 Actively Recruiting
Mycosis Fungoides
6 Actively Recruiting
Phase 2, Phase 1
Procarbazine treatment
0 Actively Recruiting
melanoma
0 Actively Recruiting
Soft Tissue Sarcoma
54 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1
Advance Directives
0 Actively Recruiting
Glioblastoma
65 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3
Disease Progression
22 Actively Recruiting
Phase 2, Phase 4, Phase 1, Not Applicable, Phase 3, Early Phase 1
Neuroblastoma
0 Actively Recruiting
Sarcoma, Ewing
0 Actively Recruiting
Nitrosourea treatment
0 Actively Recruiting
Primary Central Nervous System Lymphoma (PCNSL)
15 Actively Recruiting
Phase 1, Phase 2
Advance Directives
0 Actively Recruiting
Radiotherapy
6 Actively Recruiting
Phase 1, Not Applicable, Phase 3, Phase 2

Temozolomide Reviews: What are patients saying about Temozolomide?

3.7Patient Review
6/7/2009
Temozolomide for A Type of Brain Cancer - Anaplastic Astrocytoma
This can help take the edge off of pain.
3.7Patient Review
11/1/2007
Temozolomide for Malignant Brain Tumor Glioblastoma
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about temozolomide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of chemotherapy is temozolomide?

"The drug Temozolomide is an anti-cancer chemotherapy drug that works by classified as an "alkylating agent.""

Answered by AI

How toxic is temozolomide?

"The most common side effects of temozolomide are gastrointestinal problems, such as nausea, vomiting, and appetite loss. Anti-emetics were given to 179 out of 244 patients who experienced nausea and vomiting."

Answered by AI

What is temozolomide used for?

"Temozolomide is a cancer medication used to treat brain cancer in patients whose tumors have returned or been newly diagnosed. It is classified as an antineoplastic medication."

Answered by AI

What are temozolomide side effects?

"Common side effects of this medication include nausea, vomiting, loss of appetite, changes in taste, and constipation. You may also experience tiredness, dizziness, headache, or trouble sleeping. These side effects are usually mild and improve over time. If you experience severe nausea or vomiting, your doctor may prescribe medication to help relieve these symptoms."

Answered by AI

Clinical Trials for Temozolomide

Have you considered Temozolomide clinical trials? We made a collection of clinical trials featuring Temozolomide, we think they might fit your search criteria.
Have you considered Temozolomide clinical trials? We made a collection of clinical trials featuring Temozolomide, we think they might fit your search criteria.
Have you considered Temozolomide clinical trials? We made a collection of clinical trials featuring Temozolomide, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top